PET8 Antibody

What is the PAQR8 antibody and what are its primary applications in research?

The PAQR8 antibody is a polyclonal antibody generated from rabbits immunized with a KLH-conjugated synthetic peptide corresponding to amino acids 326-354 from the C-terminal region of human PAQR8. PAQR8 (Progestin and adipoQ receptor family member 8) functions as a plasma membrane progesterone receptor coupled to G proteins, acting through a G(i)-mediated pathway .

Primary research applications include:

• Western blotting for detection of PAQR8 protein expression

• Investigating progesterone receptor signaling in reproductive biology

• Studying the role of PAQR8 in oocyte maturation processes

• Examining membrane-initiated steroid signaling pathways

• Investigating PAQR8 interaction with steroid hormones including dehydroepiandrosterone (DHEA), pregnanolone, pregnenolone, and allopregnanolone

When conducting research with PAQR8 antibodies, optimal dilution for Western blotting is 1:1000, and the antibody should be stored refrigerated at 2-8°C for short-term use (up to 2 weeks) or at -20°C in small aliquots for long-term storage to prevent freeze-thaw cycles .

How do anti-CD8 antibodies function in immuno-PET imaging applications?

Anti-CD8 immuno-PET imaging antibodies function as non-invasive tools to monitor CD8+ T cell localization, migration, and expansion in vivo. These engineered antibody fragments contain variable regions that bind specifically to CD8 receptors on cytotoxic T cells while being radiolabeled for detection via PET imaging .

The functional mechanism involves:

• Engineered antibody fragments (e.g., minibodies) retaining CD8 antigen specificity

• Conjugation with chelators such as S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid

• Radiolabeling with positron-emitting isotopes (commonly 64Cu)

• Intravenous administration and targeted binding to CD8+ cells in lymphoid tissues

• Detection and quantification using PET imaging technology

Importantly, the engineered minibody (Mb) format exhibits rapid clearance (5-12 hour terminal half-life) compared to intact antibodies (1-3 week half-life), allowing for higher-contrast images at earlier timepoints post-injection while delivering lower radiation doses to patients .

What is the difference between PAQR8 antibody detection methods and immuno-PET imaging technologies?

The fundamental methodological difference lies in the application context: PAQR8 antibodies are primarily used for biochemical and cellular analysis of hormone receptor function in reproductive biology, while immuno-PET imaging antibodies are specifically engineered for in vivo molecular imaging of immune cell populations, particularly in the context of cancer immunotherapy monitoring and lymphoma assessment .

How can engineered antibody fragments improve immuno-PET imaging compared to conventional intact antibodies?

Engineered antibody fragments provide several significant advantages over intact antibodies for immuno-PET imaging applications:

Researchers have demonstrated these advantages experimentally, showing that anti-CD8 minibodies produce high-contrast immuno-PET images just 4 hours post-injection, with specific uptake in spleen and lymph nodes of antigen-positive mice, while blood activity levels drop to 0.3-0.9%ID/g compared to 6-7.5%ID/g for other minibody formats at 6 hours post-injection .

What methodological approaches are used to develop oligomer-specific antibodies for amyloid beta detection?

Development of oligomer-specific antibodies for amyloid beta (Aβ) detection employs a sophisticated two-step rational design method that overcomes the challenges posed by the transient nature of oligomeric species:

• Antigen scanning phase:

  • Design an initial panel of antibodies targeting different epitopes covering the entire Aβ sequence

  • Evaluate binding characteristics through in vitro assays to identify regions exposed in oligomers but not in fibrillar deposits

  • This systematic epitope mapping approach doesn't require prior knowledge of oligomer structure

• Epitope mining phase:

  • Design a second panel of antibodies specifically targeting the regions identified during the scanning phase

  • Perform binding assays to identify the candidate with highest specificity and affinity for oligomeric species

  • Further refine candidates through structural optimization

The rational complementary peptide design procedure involves:

• Collecting protein fragments from the Protein Data Bank that face target epitopes in β-strand conformations

• Building complementary peptides by merging fragments using the cascade method

• Applying strict rules for fragment joining: same β-strand type, partial overlap, and identical backbone hydrogen-bond patterns

This method has successfully yielded antibodies capable of accurately detecting and quantifying Aβ oligomers in vitro and in biological samples from C. elegans and mouse models of Alzheimer's disease, demonstrating its applicability for creating diagnostic and research tools for protein misfolding disorders .

How can CD8-targeted immuno-PET imaging be utilized in monitoring immunotherapy efficacy?

CD8-targeted immuno-PET imaging offers powerful capabilities for monitoring immunotherapy efficacy through non-invasive, quantitative assessment of cytotoxic T cell dynamics:

• Baseline assessment:

  • Quantify initial CD8+ T cell presence in tumors and lymphoid organs

  • Establish patient-specific reference points for subsequent monitoring

  • Identify patients most likely to benefit from immunotherapies that depend on CD8+ T cell function

• Longitudinal monitoring:

  • Track CD8+ T cell infiltration into tumors following immunotherapy administration

  • Assess expansion of CD8+ T cells in lymphoid organs as evidence of immune activation

  • Measure changes in CD8+ T cell localization patterns over the treatment course

• Response prediction and stratification:

  • Early changes in CD8+ T cell tumor infiltration can predict eventual clinical outcomes

  • Distinguish between pseudoprogression and true progression during immune checkpoint inhibitor therapy

  • Identify responders vs. non-responders earlier than conventional imaging methods

• Mechanistic insights:

  • Evaluate whether treatment failure is due to inadequate T cell expansion, poor tumor infiltration, or post-infiltration dysfunction

  • Guide rational combinations of immunotherapeutic agents based on observed immune response patterns

  • Correlate imaging findings with other immune monitoring approaches such as liquid biopsies

Implementation requires careful consideration of radionuclide selection, with 64Cu (12.7-hour half-life) providing an optimal balance between image quality and radiation exposure for clinical translation .

What are the recommended protocols for radiolabeling antibody fragments for immuno-PET imaging studies?

For optimal radiolabeling of antibody fragments for immuno-PET imaging, researchers should follow these methodological steps:

• Antibody fragment preparation:

  • Express engineered antibody fragments (minibodies, diabodies) in mammalian expression systems

  • Purify using immobilized metal affinity chromatography (IMAC) or protein L chromatography

  • Verify integrity and immunoreactivity using SDS-PAGE and flow cytometry

• Chelator conjugation:

  • React antibody fragments with bifunctional chelators such as S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) at molar ratios of 1:5 to 1:10

  • Maintain pH between 8.5-9.0 during conjugation

  • Remove unreacted chelator via size exclusion chromatography

  • Determine chelator-to-protein ratio using radiometric or spectrophotometric methods

• Radiolabeling procedure:

  • Add 64Cu in acetate buffer (pH 5.5-6.0) to chelator-conjugated antibody

  • Incubate at 37°C for 30-60 minutes with gentle agitation

  • Assess radiochemical purity using instant thin-layer chromatography (ITLC)

  • Purify radiolabeled construct using PD-10 size exclusion columns

  • Filter sterilize through 0.2 μm filters before in vivo use

• Quality control parameters:

  • Radiochemical purity should exceed 95%

  • Immunoreactivity should be maintained above 70% of the unconjugated fragment

  • Specific activity typically ranges from 0.2-1.0 mCi/nmol for optimal imaging

  • Stability testing in serum should show <10% transchelation after 24 hours

This protocol typically yields radiolabeled antibody fragments with high radiochemical purity and preserved immunoreactivity, enabling high-contrast PET imaging at 4 hours post-injection with target-to-background ratios superior to those achieved with intact antibodies .

What methods should be used to validate PAQR8 antibody specificity in experimental applications?

Comprehensive validation of PAQR8 antibody specificity requires a multi-faceted approach:

• Western blotting validation:

  • Test antibody against lysates from tissues with known high (hypothalamus, spinal cord, kidney, testis) and low PAQR8 expression

  • Include positive control lysates from PAQR8-overexpressing cells

  • Perform peptide competition assays using the immunizing peptide (amino acids 326-354) to confirm binding specificity

  • Verify a single band at the expected molecular weight of approximately 40 kDa

• Knockout/knockdown validation:

  • Compare antibody reactivity between wild-type and PAQR8 knockout/knockdown samples

  • Use CRISPR/Cas9 or siRNA approaches for generating negative controls

  • Document complete absence or significant reduction of signal in depleted samples

• Cross-reactivity assessment:

  • Test against recombinant proteins for related PAQR family members

  • Examine reactivity across species (confirmed reactivity for human and mouse)

  • Evaluate potential cross-reactivity with other membrane progesterone receptors

• Immunocytochemistry validation:

  • Confirm membrane localization consistent with known PAQR8 distribution

  • Verify colocalization with the lysosomal protein CTSD/cathepsin D as reported

  • Compare staining patterns with alternative PAQR8 antibodies targeting different epitopes

• Flow cytometry validation:

  • Test antibody recognition of native protein in intact cells

  • Compare staining between cell lines with varying PAQR8 expression levels

  • Include appropriate isotype controls to assess non-specific binding

A validated PAQR8 antibody should demonstrate consistent results across multiple validation methods, showing specificity for the target protein at the expected molecular weight and cellular localization, with minimal cross-reactivity to related proteins .

How can researchers quantitatively assess CD8+ T cell populations using immuno-PET imaging?

Quantitative assessment of CD8+ T cell populations using immuno-PET imaging requires rigorous methodology:

• Image acquisition protocols:

  • Inject radiolabeled anti-CD8 minibodies at standardized doses (typically 1.85-3.7 MBq/10-20 μg)

  • Acquire PET scans 4 hours post-injection (optimal timing for minibody-based tracers)

  • Perform simultaneous CT imaging for anatomical co-registration

  • Use standardized acquisition parameters (10-minute static scans, 350-650 keV energy window)

• Standardized image analysis:

  • Draw 3D regions of interest (ROIs) around lymphoid organs and tumors

  • Calculate standardized uptake values (SUVs) using the formula:
    SUV = (activity concentration in ROI × body weight) ÷ injected dose

  • Use mean or maximum SUV metrics depending on research question

  • Account for partial volume effects when quantifying small structures like lymph nodes

• Calibration procedures:

  • Establish correlation between PET signal and absolute CD8+ T cell numbers using flow cytometry of harvested tissues

  • Develop standard curves relating SUV to CD8+ cell concentration

  • Research has shown that approximately 70,000-120,000 CD8+ cells can be detected in a mouse lymph node using this approach

• Validation methods:

  • Perform blocking studies with unlabeled antibody to confirm binding specificity

  • Include immunodeficient controls to establish background signal levels

  • Compare results between antigen-positive and antigen-negative tissues

• Longitudinal monitoring considerations:

  • Use consistent imaging protocols across timepoints

  • Consider correction factors for inter-scan variability

  • Account for potential changes in antibody biodistribution due to treatment effects

This quantitative approach enables researchers to monitor changes in CD8+ T cell distribution and abundance over time, with applications in immunotherapy monitoring and disease progression assessment .

What are common troubleshooting approaches for non-specific binding in PAQR8 antibody experiments?

Non-specific binding issues with PAQR8 antibodies can significantly impact experimental results. Here are methodological troubleshooting approaches:

• Optimizing blocking conditions:

  • Test different blocking agents (5% non-fat milk, 5% BSA, commercial blocking solutions)

  • Extend blocking time to 2 hours at room temperature or overnight at 4°C

  • Add 0.1-0.3% Tween-20 to blocking and antibody dilution buffers to reduce hydrophobic interactions

  • For tissues with high endogenous biotin, use avidin/biotin blocking kits before primary antibody incubation

• Antibody dilution optimization:

  • Perform systematic dilution series beyond the recommended 1:1000 dilution

  • Create a dilution curve (1:500 to 1:5000) to identify optimal signal-to-noise ratio

  • Consider using antibody dilution buffers with protein carriers and mild detergents

• Cross-adsorption protocols:

  • Pre-adsorb antibody with tissue/cell lysates from PAQR8-negative samples

  • Implement peptide competition controls using the immunizing peptide (amino acids 326-354)

  • For tissues with high background, pre-incubate sections with 10% serum from the secondary antibody host species

• Wash optimization:

  • Increase wash buffer stringency (PBS-T with 0.1-0.3% Tween-20)

  • Extend washing times and increase the number of wash steps

  • Use high-salt wash buffers (up to 500 mM NaCl) for particularly problematic samples

• Secondary antibody considerations:

  • Test highly cross-adsorbed secondary antibodies

  • Ensure secondary antibody is raised against the host species of the primary antibody

  • Run secondary-only controls to assess direct non-specific binding

• Sample preparation factors:

  • Optimize fixation protocols (overfixation can increase background)

  • For membrane proteins like PAQR8, avoid harsh detergents that may alter epitope conformation

  • Ensure complete protein denaturation for Western blotting applications

By systematically implementing these approaches, researchers can significantly improve signal specificity when using PAQR8 antibodies in various experimental applications .

How can researchers address challenges in quantifying PET signals from small lymphoid structures?

Quantifying PET signals from small lymphoid structures presents unique challenges due to partial volume effects and limited spatial resolution. Researchers can employ these methodological approaches:

• Partial volume correction techniques:

  • Implement recovery coefficient methods based on structure size

  • Apply geometric transfer matrix (GTM) algorithms that account for spillover between adjacent regions

  • Use anatomy-guided correction based on high-resolution CT or MRI co-registration

  • Research has shown that lymph node uptake determined from PET images is typically lower than ex vivo biodistribution values due to these effects

• Advanced reconstruction algorithms:

  • Utilize point spread function (PSF) modeling during image reconstruction

  • Implement time-of-flight capabilities if available on the PET scanner

  • Optimize reconstruction parameters (iterations, subsets) for small structure visualization

  • Apply appropriate post-reconstruction filters to balance noise and resolution

• Standardized quantification approaches:

  • Use consistent region-of-interest (ROI) drawing methodologies

  • Consider maximum voxel value (SUVmax) for small structures rather than mean values

  • Implement automatic or semi-automatic segmentation algorithms

  • Normalize uptake to reference tissues for improved inter-subject comparison

• Validation strategies:

  • Perform ex vivo biodistribution studies to correlate imaging findings with actual tissue uptake

  • Develop phantom studies with simulated lymph nodes of various sizes to establish size-dependent correction factors

  • Use flow cytometry to determine actual CD8+ cell numbers for calibration purposes

• Statistical considerations:

  • Account for partial volume effects in statistical analyses

  • Consider using size-dependent weighting factors

  • Implement mixed-effects models that account for measurement uncertainty

  • Calculate minimum detectable differences based on known resolution limitations

These techniques can significantly improve the accuracy of lymphoid tissue quantification in immuno-PET studies, with research demonstrating the ability to detect approximately 70,000-120,000 CD8+ cells in mouse lymph nodes despite resolution limitations .

What approaches are recommended for analyzing conflicting data between in vitro antibody binding assays and in vivo imaging results?

When researchers encounter discrepancies between in vitro antibody binding assays and in vivo imaging results, the following methodological approaches can help resolve these conflicts:

• Systematic evaluation of pharmacokinetic factors:

  • Analyze antibody biodistribution patterns at multiple timepoints

  • Calculate area under the curve (AUC) for target and non-target tissues

  • Consider the impact of "antigen sink" effects, which can cause rapid clearance of antibodies targeting abundant antigens

  • Assess potential differences in antibody stability in vitro versus in vivo

• Epitope accessibility assessment:

  • Compare native versus denatured antigen recognition

  • Evaluate the impact of the tissue microenvironment on epitope masking

  • Consider differential post-translational modifications between in vitro and in vivo conditions

  • Perform immunohistochemistry on tissue sections to bridge in vitro and in vivo findings

• Antibody format considerations:

  • Analyze how antibody size and format affect tissue penetration

  • Evaluate the impact of radiolabeling on antibody affinity and specificity

  • Consider the effect of valency (monovalent vs. bivalent binding) on apparent affinity

  • Compare full antibodies versus fragments in parallel experiments

• Biological variables reconciliation:

  • Account for differences in receptor density between cell lines and tissues

  • Consider the impact of receptor internalization kinetics

  • Evaluate competitive binding from endogenous ligands in vivo

  • Assess how blood flow and vascular permeability affect antibody delivery

• Technical validation approaches:

  • Perform blocking studies using excess unlabeled antibody

  • Include appropriate positive and negative controls in both settings

  • Utilize multiple antibodies targeting different epitopes of the same protein

  • Cross-validate findings using orthogonal detection methods

• Quantitative harmonization:

  • Develop mathematical models relating in vitro binding parameters to in vivo distribution

  • Establish correction factors for known systematic differences

  • Use ex vivo binding assays on tissues from imaged subjects as an intermediate validation

By systematically addressing these factors, researchers can reconcile conflicting data and develop more accurate interpretations of antibody-based experimental results across different experimental contexts .

What are emerging applications of dual-labeled antibodies combining PET imaging with optical detection?

Dual-labeled antibodies that combine PET imaging capabilities with optical detection represent an exciting frontier in molecular imaging research:

• Integrated surgical guidance applications:

  • Preoperative PET imaging for macroscopic tumor localization

  • Intraoperative fluorescence guidance for precise tumor margin delineation

  • Real-time assessment of lymph node involvement during surgery

  • Post-resection cavity scanning to confirm complete tumor removal

• Complementary scale imaging approaches:

  • PET component provides whole-body biodistribution and quantification

  • Optical component enables microscopic cellular and subcellular resolution

  • Correlation of macroscopic PET signal with microscopic disease features

  • Bridging in vivo imaging with ex vivo histopathology

• Advanced multiparametric tissue characterization:

  • Simultaneous assessment of multiple biomarkers through spectral unmixing

  • Combination with activatable fluorescent probes for reporting on tissue microenvironment

  • Integration with photoacoustic imaging for additional contrast mechanisms

  • Development of theranostic approaches combining imaging with photodynamic therapy

• Technical implementation strategies:

  • Site-specific conjugation of different reporters to maintain immunoreactivity

  • Selection of compatible radioisotope-fluorophore pairs to minimize interference

  • Development of bifunctional chelators with integrated fluorescent properties

  • Optimization of detection sensitivity across imaging modalities

• Preclinical validation methodologies:

  • Correlation of PET and optical signals in tissue phantoms

  • Quantitative assessment of signal co-localization in animal models

  • Determination of minimum detectable cell numbers for each modality

  • Evaluation of signal persistence for optimal surgical timing windows

This approach combines the strengths of both modalities—whole-body sensitivity and quantification from PET with high-resolution optical detection—creating powerful tools for translational research and clinical applications in immunotherapy monitoring, tumor detection, and image-guided interventions .

How might advances in antibody engineering impact the development of next-generation immuno-PET tracers?

Emerging advances in antibody engineering are poised to revolutionize immuno-PET tracer development through several innovative approaches:

• Site-specific conjugation technologies:

  • Incorporation of unnatural amino acids for orthogonal chemistry

  • Enzymatic approaches using sortase A or transglutaminase

  • Strain-promoted azide-alkyne cycloaddition chemistry

  • These methods preserve immunoreactivity by ensuring chelator placement away from antigen-binding regions

• Novel antibody formats:

  • Single-domain antibodies (nanobodies) with superior tissue penetration

  • Bispecific constructs targeting both tumor antigens and T cells

  • Pretargeting strategies using biorthogonal chemistry

  • Albumin-binding domains for optimized pharmacokinetics

• Affinity modulation approaches:

  • Engineering of binding kinetics (kon/koff rates) rather than equilibrium constants

  • Temperature-dependent binding for selective tumor retention

  • pH-sensitive binding for differential behavior in tumor microenvironments

  • Computational design of complementarity-determining regions (CDRs)

• Radioisotope selection optimization:

  • Matching physical half-lives with biological clearance rates

  • Exploration of alternative positron emitters (89Zr, 68Ga, 18F-labeled prosthetic groups)

  • Development of radiometal-chelator pairs with enhanced stability

  • Consideration of theranostic pairs for combined imaging and therapy

• Smart activation systems:

  • Protease-activatable tracers that amplify signal in inflammatory environments

  • Photocaged antibody fragments activated by external light sources

  • Conditional binding dependent on multiple biomarker presence

  • Cell-penetrating capabilities triggered by specific microenvironmental conditions

These engineering advances could lead to immuno-PET tracers with significantly improved targeting efficiency, reduced off-target binding, faster clearance from non-target tissues, and enhanced image contrast, ultimately enabling earlier detection of small cell populations and more accurate therapy monitoring .

What are the key considerations researchers should evaluate when selecting between different antibody-based imaging approaches?

When selecting between different antibody-based imaging approaches, researchers should systematically evaluate these key considerations:

• Research question alignment:

  • Match temporal resolution requirements with antibody format kinetics

  • Consider whether whole-body imaging is necessary or if regional imaging suffices

  • Determine if quantitative measurements or qualitative assessment is needed

  • Assess whether longitudinal monitoring is required

• Target characteristics evaluation:

  • Analyze target expression levels and accessibility

  • Consider internalization rate of the target receptor

  • Evaluate potential for antigen shedding or modulation

  • Assess target heterogeneity across tissues of interest

• Technical implementation factors:

  • Available imaging infrastructure (PET, SPECT, optical)

  • Institutional radiochemistry capabilities

  • Cost considerations for reagents and imaging time

  • Required spatial and temporal resolution

• Biological impact assessment:

  • Potential for antibody-mediated biological effects (e.g., depletion, activation)

  • Immunogenicity concerns for repeated administration

  • Radiation exposure considerations for subjects

  • Toxicity profile of the complete construct

• Practical implementation considerations:

  • Shelf-life and stability of the imaging agent

  • Ease of production and quality control

  • Reproducibility of results between subjects

  • Regulatory approval pathway for clinical translation

• Comparative advantage analysis:

  Antibody Format	Optimal Imaging Time	Best Applications	Limitations
  Intact IgG	24-96 hours	High-sensitivity detection	Slow clearance, potential depletion effects
  Minibody	4-12 hours	Same-day imaging, reduced radiation	Moderate tumor penetration
  Diabody/scFv	1-6 hours	Rapid screening, dynamic studies	Lower absolute uptake in target tissues
  Nanobody	1-2 hours	Fast imaging, small structure penetration	Limited valency, potential immunogenicity

By systematically evaluating these considerations, researchers can select the optimal antibody-based imaging approach for their specific experimental or clinical needs, balancing factors such as image quality, timing, biological effects, and practical implementation requirements .

How might the combination of immuno-PET imaging and PAQR8 research contribute to advances in reproductive biology and immunotherapy?

The convergence of immuno-PET imaging technologies with PAQR8 research presents unique opportunities to advance both reproductive biology and immunotherapy through novel interdisciplinary approaches:

• Monitoring hormone receptor dynamics in vivo:

  • Development of radiolabeled progestins to track PAQR8-mediated signaling

  • Non-invasive assessment of receptor expression changes during reproductive cycles

  • Visualization of receptor trafficking in response to hormone exposure

  • Correlation of progesterone signaling with immune cell recruitment in reproductive tissues

• Reproductive immunology investigations:

  • Simultaneous tracking of PAQR8 expression and immune cell infiltration

  • Visualization of CD8+ T cell dynamics at the maternal-fetal interface

  • Assessment of hormone receptor expression on specific immune cell subsets

  • Monitoring immunomodulatory effects of pregnancy-related hormones

• Cancer immunotherapy applications:

  • Evaluation of PAQR8-mediated effects on tumor-infiltrating lymphocytes

  • Investigation of progesterone signaling impacts on immunotherapy efficacy

  • Development of combined approaches targeting both hormone receptors and immune checkpoints

  • Personalized therapy selection based on receptor expression patterns

• Technological synergies:

  • Application of rational antibody design methods across both research areas

  • Development of dual-specificity antibodies targeting both immune cells and hormone receptors

  • Implementation of multimodal imaging approaches combining functional and molecular information

  • Creation of theranostic agents for hormone-responsive cancers

• Translational research pathways:

  • Improved understanding of hormone-immune interactions in reproductive disorders

  • Development of novel contraceptive approaches based on PAQR8 targeting

  • Refinement of hormone therapies based on immune monitoring

  • Creation of precision medicine strategies for hormone-responsive cancers